IBTJ

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change -0.06
Percentage change -0.26	%

Held by: LDRT

Category	Bonds - Treasury & Government	Asset Type	Bonds	Tags	U.S.	Return% 1Y	4.09%	Shs Outstand		Perf Week	-0.81%
Sponsor	Blackrock (iShares)	ETF Type		Tags	fixed-income	Return% 3Y	-2.28%	Total Holdings	25	Perf Month	0.21%
Fund Family		Bond Type		Tags	treasuries	Return% 5Y	-	AUM	419.09M	Perf Quarter	-3.49%
Index	ICE 2029 Maturity US Treasury Index	Average Maturity		Tags	bonds	Return% 10Y		NAV%		Perf Half Y	0.02%
Index Weighting		Commodity Type		Tags	-	Return% SI		NAV/sh		Perf Year	-0.95%
Active/Passive		Quant Type		Tags	-	Flows% 1M	11.73%	52W Range	20.95 - 22.22	Perf YTD	-1.54%
Dividend TTM	0.77 (3.59%)	ESG Type		Tags	-	Flows% 3M	18.62%	52W High	-3.49%	Beta	0.11
Dividend Ex-Date	Dec 02, 2024	Dividend Type		Sector/Theme		Flows% YTD	148.15%	52W Low	2.36%	ATR (14)	0.06
Expense	0.07%	Structure Type		Region		Flows% 1Y		RSI (14)	40.70	Volatility	0.20% 0.23%
Option/Short	No / Yes	Growth/Value		Dev/Emerg		Flows% 3Y		Rel Volume	1.09	Prev Close	21.50
Inverse/Leveraged		Market Cap		Currency		Flows% 5Y		Avg Volume	110.38K	Price	21.44
SMA20	-0.30%	SMA50	-0.60%	SMA200	-0.47%	Trades		Volume	120,787	Change	-0.26%

Jan-28-21 04:30PM	Sonoma Pharmaceuticals and Microderm Technologies Announce that Dermodacyn® Disinfecting Solution is Now Available in Hong Kong and Thailand (Business Wire)
Jan-27-21 02:30PM	ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sonoma Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm (ACCESSWIRE)
Jan-18-21 06:00PM	ROSEN, GLOBAL INVESTOR COUNSEL, Continues To Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. - SNOA (PR Newswire)
Jan-14-21 11:45AM	SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Sonoma Pharmaceuticals, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm (ACCESSWIRE)
Jan-11-21 05:30PM	Sonoma Pharmaceuticals to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference (Business Wire)
04:07PM	Loading…
Dec-24-20 04:07PM	ROSEN, A LEADING INVESTOR FIRM, Continues To Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. SNOA (Business Wire)
Dec-23-20 12:40AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sonoma Pharmaceuticals, Inc. - SNOA (ACCESSWIRE)
Dec-19-20 11:35PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sonoma Pharmaceuticals, Inc. - SNOA (GlobeNewswire)
Dec-17-20 06:17PM	ROSEN, RESPECTED INVESTOR COUNSEL, Continues Its Investigation of Securities Claims Against Sonoma Pharmaceuticals, Inc. SNOA (GlobeNewswire)
04:10PM	Sonoma Pharmaceuticals Announces Partnership with Gabriel Science, LLC For Dental Markets (Business Wire)
Dec-16-20 04:47PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sonoma Pharmaceuticals, Inc. - SNOA (Newsfile)
Dec-12-20 08:08PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sonoma Pharmaceuticals, Inc. - SNOA (GlobeNewswire)
Dec-11-20 10:37AM	Sonoma Pharmaceuticals News Alert: Why SNOA Stock Is Rocketing Higher Today (InvestorPlace)
Dec-10-20 04:10PM	Sonoma Pharmaceuticals and Crown Laboratories Announce an Exclusive Partnership to Launch Microcyn® Technology-Based Anti-Itch Over-the-Counter Products (Business Wire)
Dec-09-20 11:30PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sonoma Pharmaceuticals, Inc. - SNOA (ACCESSWIRE)
03:47PM	Loading…
Dec-08-20 03:47PM	ROSEN, GLOBAL INVESTOR COUNSEL, Continues Its Investigation of Securities Claims Against Sonoma Pharmaceuticals, Inc. - SNOA (Newsfile)
Dec-07-20 08:13PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sonoma Pharmaceuticals, Inc. - SNOA (GlobeNewswire)
Dec-05-20 09:20PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sonoma Pharmaceuticals, Inc. - SNOA (ACCESSWIRE)
Dec-02-20 02:15PM	IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sonoma Pharmaceuticals, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm (ACCESSWIRE)
09:25AM	ROSEN, RESPECTED INVESTOR COUNSEL, Continues to Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. SNOA (GlobeNewswire)
Dec-01-20 01:15PM	IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Sonoma Pharmaceuticals, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm (ACCESSWIRE)
Nov-30-20 09:00PM	SONOMA PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. is Investigating Sonoma Pharmaceuticals, Inc. on Behalf of Sonoma Stockholders and Encourages Investors to Contact the Firm (GlobeNewswire)
08:46PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Sonoma Pharmaceuticals, Inc. SNOA (GlobeNewswire)
Nov-29-20 07:45AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sonoma Pharmaceuticals, Inc. - SNOA (ACCESSWIRE)
Nov-27-20 10:17AM	ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sonoma Pharmaceuticals, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm (Business Wire)
10:00AM	INDIVIDUAL INVESTOR ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Investigates Securities Claims Against Sonoma Pharmaceuticals, Inc. Seeking Recovery of Investor Losses - SNOA (ACCESSWIRE)
Nov-26-20 01:00PM	IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sonoma Pharmaceuticals, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm (ACCESSWIRE)
Nov-25-20 11:20PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sonoma Pharmaceuticals, Inc. - SNOA (PR Newswire)
08:26PM	Sonoma Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm (GlobeNewswire)
11:00AM	Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Sonoma Pharmaceuticals, Inc. (SNOA) Investigation (ACCESSWIRE)
09:46AM	Loading…
09:46AM	INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Sonoma Pharmaceuticals, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm (Newsfile)
Nov-24-20 08:47PM	ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. - SNOA (PR Newswire)
01:41PM	INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sonoma Pharmaceuticals, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm (Business Wire)
01:33PM	ROSEN, RESPECTED INVESTOR COUNSEL, Continues to Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. - SNOA (Newsfile)
10:36AM	EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Sonoma Pharmaceuticals, Inc. SNOA (Business Wire)
Nov-20-20 04:21PM	Sonoma Pharmaceuticals Reports Second Quarter FY 2021 Financial Results (Business Wire)

iShares iBonds Dec 2029 Term Treasury ETF seeks to track the investment results of the ICE 2029 Maturity U.S. Treasury Index composed of U.S. Treasury bonds maturing in 2029. The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in U.S. Treasury securities that BFA believes will help the fund track the underlying index. The underlying index consists of publicly-issued U.S. Treasury securities that are scheduled to mature between January 1, 2029 and December 15, 2029, inclusive.

open in yahoo | open in marketwatch | open in google

iShares iBonds Dec 2029 Term Treasury ETF

Upgrade your FINVIZ experience